Magnesium Biomarker Cohort 2

Magnesium Study

We are seeking approximately 100 participants to take part in a 12-week study evaluating the effectiveness of Qualia Magnesium+, a dietary supplement designed to potentially support magnesium levels, sleep quality, and stress reduction.

This is a randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either Qualia Magnesium+ or a placebo, and neither participants nor researchers will know which study product was received until after the study ends.

Participants will take 2 capsules daily in the evening, with or without food, for 12 weeks. The study will involve regular check-ins, self-report questionnaires, and blood tests conducted at a local facility (such as Quest Diagnostics) to measure red blood cell (RBC) and serum magnesium levels.

Upon completion of the study, participants will receive a $300 credit at Qualia Life Sciences.

Participation Requirements:

• Healthy adults 21 years or older
• Can read and write English
• Agree to provide a valid cell phone number and are willing to receive communications through text
• Willing to not consume any supplements containing magnesium starting about 2 weeks prior to the baseline magnesium blood test and continuing through the intervention period.
• Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly with the exception of those containing magnesium
• Willing to complete questionnaires, records, and diaries associated with the study.
• Willing to visit a local blood draw facility (must live within 20 miles of one)
• Willing to pause any magnesium-containing supplements during the study period

Exclusion Criteria:

• Women who are pregnant, breastfeeding or planning to become pregnant during the trial
• Known food intolerances/allergy to any ingredients in the product
• Having any of the following conditions: Psychiatric conditions, neurologic disorders, high blood pressure, heart conditions, endocrine disorders, or cancer
• Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
• On immunosuppressive therapy

This study is being conducted by Qualia Life Science